Doubling the Dose of Glatiramer Acetate Does Not Increase Efficacy
Posted Jan 14 2009 8:23pm
Information contributed by Cherie Binns, R.N.
Medscape News Alison Palkhivala
September 22, 2008 (Montreal, Quebec) — Doubling the dose of glatiramer acetate from 20 to 40 mg/mL did not improve clinical or imaging outcomes after a year of therapy in patients with multiple sclerosis (MS).
Both doses of the drug performed very well, although the higher dose appeared to reduce the number of gadolinium-enhancing and new T2 lesions on magnetic resonance imaging (MRI) sooner, according to research presented here at the World Congress on Treatment and Research in Multiple Sclerosis: 2008 Joint Meeting of the American, European, and Latin America Committees on Treatment and Research in Multiple Sclerosis (ACTRIMS, ECTRIMS, LACTRIMS). Lead author Giancarlo Comi, MD, a professor of neurology and chair of the neurology department at the University Vita Salute, Scientific Institute San Raffaele, in Milan, Italy, presented the results.
Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog. ============================================